GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (XSWX:ZBH) » Definitions » Net Change in Cash

Zimmer Biomet Holdings (XSWX:ZBH) Net Change in Cash : CHF31 Mil (TTM As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Zimmer Biomet Holdings Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Zimmer Biomet Holdings's Net Change in Cash for the three months ended in Dec. 2023 was CHF107 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was CHF31 Mil.

Zimmer Biomet Holdings Net Change in Cash Historical Data

The historical data trend for Zimmer Biomet Holdings's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings Net Change in Cash Chart

Zimmer Biomet Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.79 163.64 -298.04 -95.77 34.68

Zimmer Biomet Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -158.09 -42.11 -9.36 -24.83 106.89

Zimmer Biomet Holdings Net Change in Cash Calculation

Zimmer Biomet Holdings's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=1367.768+-673.593+-660.275+0.778
=35

Zimmer Biomet Holdings's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=508.848+-190.948+-217.411+6.4
=107

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zimmer Biomet Holdings Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Zimmer Biomet Holdings (XSWX:ZBH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (XSWX:ZBH) » Definitions » Net Change in Cash
Comparable Companies
ALGN STE BRKR SWAV PODD BIO PEN MASI GMED INSP TSE:5212 ABT SYK MDT BSX EW DXCM SZSE:300760 XAMS:PHIA XSWX:SOON
Traded in Other Exchanges
ZBH:USA ZIM:Germany ZBH:Austria
Address
345 East Main Street, Warsaw, IN, USA, 46580
Website
https://www.zimmerbiomet.com
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.